Patents by Inventor Jim Johnston
Jim Johnston has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12139945Abstract: Aspects of the present invention relate to hinge apparatus for supporting an aperture closure member. The hinge apparatus is configurable in at least first and second configurations. The hinge apparatus includes a first hinge bracket and a second hinge bracket. A first hinge linkage member is pivotally mounted to each of the first and second hinge brackets. A second hinge linkage member is pivotally mounted to each of the first and second hinge brackets. A latching mechanism is provided for selectively latching the hinge apparatus. The latching mechanism is operable to inhibit movement of the first and second hinge linkage members relative to each other to latch the hinge apparatus. The present invention also relates to a carrier assembly for carrying an aperture closure member; and a vehicle having a carrier assembly.Type: GrantFiled: March 9, 2020Date of Patent: November 12, 2024Assignee: JAGUAR LAND ROVER LIMITEDInventors: Nicholas Hook, David Rathbone, Jim Johnston, Mark Langstone
-
Publication number: 20220178186Abstract: Aspects of the present invention relate to hinge apparatus (3-n) for supporting an aperture closure member (4). The hinge apparatus (3-1, 3-2) (3-n) is configurable in at least first and second configurations. The hinge apparatus (3-1, 3-2) (3-n) includes a first hinge bracket (10) (10) and a second hinge bracket (11) (11). A first hinge linkage member (15) is pivotally mounted to each of the first and second hinge brackets (10, 11) (10, 11). A second hinge linkage member (16) (16) is pivotally mounted to each of the first and second hinge brackets (10, 11) (10, 11). A latching mechanism (25) (25) is provided for selectively latching the hinge apparatus (3-1, 3-2) (3-n). The latching mechanism (25) (25) is operable to inhibit movement of the first and second hinge linkage members (15, 16) (15, 16) relative to each other to latch the hinge apparatus (3-1, 3-2) (3-n).Type: ApplicationFiled: March 9, 2020Publication date: June 9, 2022Inventors: Nicholas HOOK, David RATHBONE, Jim JOHNSTON, Mark LANGSTONE
-
Patent number: 9101253Abstract: One exemplary aspect comprises a device for removing material from a surface, comprising: (a) a head component comprising a first handle portion and a first scraper portion; and (b) a shaft component comprising a rod portion and a second handle portion. In various exemplary embodiments: (1) the first handle portion is suitable for receiving a portion of a user's hand; (2) the head component further comprises a second scraper portion; (3) the second scraper portion comprises a blade with a serrated edge; (4) the second scraper portion comprises a squeegee blade; (5) the second scraper portion comprises a metal blade; (6) the head component further comprises a third scraper portion; (7) the first handle portion comprises a rubber grip component; and (8) the rod portion comprises a telescoping rod.Type: GrantFiled: January 9, 2013Date of Patent: August 11, 2015Assignee: QUIRKY, INC.Inventors: Jim Johnstone, John Thomas Jacobsen, Jessica Fugler
-
Patent number: 8747849Abstract: Described are specific binding members e.g. antibodies which may be used in the treatment of diseases associated with cathepsin S activity. The specific binding members bind cathepsin S and inhibit its proteolytic activity. The binding members may be used in the treatment of diseases such as cancer, inflammatory diseases, neurodegenerative disorders, autoimmune disorders, and other diseases associated with excessive, deregulated or inappropriate angiogenesis.Type: GrantFiled: March 18, 2011Date of Patent: June 10, 2014Assignee: Fusion Antibodies LimitedInventors: Christopher Scott, Roberta Burden, Shane Olwill, Brian Walker, Jim Johnston
-
Publication number: 20110243955Abstract: Described are specific binding members e.g. antibodies which may be used in the treatment of diseases associated with cathepsin S activity. The specific binding members bind cathepsin S and inhibit its proteolytic activity.Type: ApplicationFiled: March 18, 2011Publication date: October 6, 2011Applicant: Fusion Antibodies LimitedInventors: Christopher Scott, Roberta Burden, Shane Olwill, Brian Walker, Jim Johnston
-
Publication number: 20110194029Abstract: Capacitive touch sensors are integrated with a head-mounted display (HMD) device or other video eyewear devices to create a more reliable and more intuitive user interface. The sensors, which may be implemented as an array, control various aspects of a left and right channel multimedia presentation, such as interpupillary distance or stereoscopic convergence, brightness, volume, or power mode.Type: ApplicationFiled: February 7, 2011Publication date: August 11, 2011Applicant: Kopin CorporationInventors: Frederick P. Herrmann, John Gassel, Jim Johnston
-
Patent number: 7939642Abstract: Described are specific binding members e.g. antibodies which may be used in the treatment of diseases associated with cathepsin S activity. The specific binding members binds cathepsin S and inhibits its proteolytic activity. The binding members may be used in the treatment of diseases such as cancer, inflammatory diseases, neurodegenerative disorders, autoimmune disorders, and other diseases associated with excessive, deregulated or inappropriate angiogenesis.Type: GrantFiled: April 10, 2006Date of Patent: May 10, 2011Assignee: Fusion Antibodies LimitedInventors: Christopher Scott, Roberta Burden, Shane Olwill, Brian Walker, Jim Johnston
-
Publication number: 20100104554Abstract: A method of inhibiting activity of a cathepsin L-like protease in cells or tissue and the use of the method in the treatment of disease such as cancer and inflammatory diseases is described. The method comprises administration of a cathepsin propeptide or a nucleic acid encoding a cathepsin propeptide. In particular embodiments, the propeptide is a Cathepsin S propeptide. Further, the use of propeptides having an Fc portion is described.Type: ApplicationFiled: March 2, 2007Publication date: April 29, 2010Applicant: Fusion Antibodies Limited, a Corporation of Great BritianInventors: Christopher Scott, Roberta Burden, Jim Johnston, Mark McCurley, Philip Snoddy, Richard Buick
-
Publication number: 20090317405Abstract: Described are specific binding members e.g. antibodies which may be used in the treatment of diseases associated with cathepsin S activity. The specific binding members bind cathepsin S and inhibit its proteolytic activity. The binding members may be used in the treatment of diseases such as cancer, inflammatory diseases, neurodegenerative disorders, autoimmune disorders, and other diseases associated with excessive, deregulated or inappropriate angiogenesis.Type: ApplicationFiled: April 10, 2006Publication date: December 24, 2009Applicant: Fusion Antibodies LimitedInventors: Christopher Scott, Roberta Burden, Shane Olwill, Brian Walker, Jim Johnston
-
Publication number: 20090068198Abstract: Described are specific binding members e.g. antibodies which may be used in the treatment of diseases associated with cathepsin S activity. The specific binding members binds cathepsin S and inhibits its proteolytic activity. The binding members may be used in the treatment of diseases such as cancer, inflammatory diseases, neurodegenerative disorders, autoimmune disorders, and other diseases associated with excessive, deregulated or inappropriate angiogenesis.Type: ApplicationFiled: April 10, 2006Publication date: March 12, 2009Applicant: The Queen's University of BelfastInventors: Christopher Scott, Roberta Burden, Shane Olwill, Brian Walker, Jim Johnston
-
Publication number: 20060234222Abstract: Described is a method of producing a soluble bioactive domain of a protein, the method comprising the step of selecting suitable soluble subunits of a protein and assessing the produced protein for desired activity. The method may comprise the steps of amplifying DNA encoding at least one candidate soluble domain, cloning the amplified DNA into at least one expression vector, using each of said vectors into which the DNA has been cloned to each transfect or transform one or more host cell strains, expressing said DNA in one or more host cell strains, and analyzing expression products from said host cells for solubility.Type: ApplicationFiled: December 30, 2002Publication date: October 19, 2006Inventors: Brendan McKeown, Christopher Scott, Alan McBride, Richard Buick, Jim Johnston